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Abstract:
To describe the fibronectin molecu1e and its role in the metastatic process of cancer. To

also show the rational behind the structure and the \vay it was reasoned. To define the method of
development for RGD inhibitory molecu1e through kno\vledge of past experiments and
conclusions. Substituting various amino acid residues into fibronectin 1ike molecules to
understand the effect each residue has in the overall stereochemistry and electrochemistry of the
fibronectjn binding site. Outlining a synthesis for one of more effective inhibiting peptide and the
discussion of its binding abilities including receptor site affinity.
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Introduction

Cancer is one of the leading killers in the industrialized nations. It stems from one
initial growth and then spreads throughout the body to overwhelm the immune system and
destroy the systems invaded. Cancers have a metastatic ability, and it is this ability that
causes most cancer deaths 1. If cancers consisted only of primary tumors, then most could
be removed surgically or treated with drugs or other chemicals; however, cancers have an
ability to move from one area to other unrelated areas of the body and start new growths.
If the metastatic process could be slowed, or better yet halted, then a huge advancement in

medical science would be made.

Cancer Metastasis

The metastatic process will be broken down into seven steps for simplicity. It
should be noted that these steps are not always independent of one another and may occur
simultaneously within the organism. These breakdowns are merely used to make each
process more understandable; it is worth noting that if any of these steps are halted, then
no secondary growth forms.
A neoplasm of unknown origin (see Figure 1) has some sort of initial (la) local
--

invasion, the cancerous cells must penetrate the neighboring tissue of the neoplasm. After
leaving the neoplasm's environment, the cancerous cells must (1) detach from the primary
tumor and survive. The cells may do this either as indivdually or as larger groupings of
cells. In order for a dissemination of the metastic cells, the transformed cells must (2)
invade local blood vessels and be (3) transported to other areas of the body via the
circulatory system. The cells moving in the blood stream then must (4) lodge into the
blood vessel wall. Experimentally, it has been shown that the arrest occurs most often in
the capillary beds; it is assumed that arrest does not occur often in the larger vessels due to
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blood shearing forces that the cells would encounter. The cells lodge at sites distal from
the primary tumor in three ways, not always independent of one another. The cells may
become physically lodged in a blood vessel or capillary bed due their size versus that of the
vessel. Malignant cells may also adhere to blood vessel walls through a specific
recognition. Experimentally, it has not been shown that malignant cells have an exclusive
mechanism with any specific cell type; however, the cells may display selective adhesion
to the blood vessel endothelium of certain organs. The lodgment occurs due to molecular
interactions between the surfaces of the malignant cell and the vessel wall; however, the
interactions are not exclusive of either adhering cells' surfaces, but rather selective for the
surfaces. Once the malignant cells are lodged on the vessel wall, (5) extravasation of the
malignant cell out of the circulatory system occur and the transformed cells migrate to a
secondary site. Once migration is complete, continued (6) growth 2 must occur.

Figure 1 The Metastatic Process as described above 2

3

Fibronectin and the Fibronectin Receptor

Fibronectin is a 440 kD extra cellular matrix protein identified important in the
selective attachment step of the metastatic process. Fibronectin is composed of two similar
polypeptide chains linked via a disulfide bridge near the carboxyl terminals. Fibronectin is
important in the secondary growth of cancer, because it provides an attachment site for the
transfonned cells free floating in the circulatory system. Fibronectin has a major binding
site composed of a three amino acid sequence. Through competitive inhibition, the
Arginine-Glycine-Aspartic Acid-(Serine), also known as the RGD(S) sequence, has been
proposed to compose the selective binding site. 2
The fibronectin receptor is glycoprotein complex composed of an alpha and beta
subunit, 150 kD and 130 kD, respectively. The fibronectin receptor itself is extremely
variable with as many as ten alpha subunits and eight beta subunits. The variability allows
the intergrin the ability to be apart of many cellular functions. 3 This variability makes the
study of the receptor difficult, so the vast majority of the research is focused on the
fibronectin itself.

Gaining Understanding of the RGD-Adhesion Site

Through experimentation, a smaller 75 kD peptide subunit containing the RGDS
sequence has the ability to adhere moderately to the transfonned cells, while a smaller 11.5
kD peptide fragment containing the RGDS fragment is not very effective in its adherence.
From this observation fibronectin was proposed to have two, maybe even three, distinct
binding sites for its adherence to metastatic cells.4
Trigramin, a snake venom, contains the RGD peptide and inhibits the attachment of
transfonned cells to fibronectin. From this it was deduced that the concept of two or three
binding sites is faulty. The snake venom inhibits attachment yet it shares no relationship
with adhesion molecules other than the RGD site. When the trigramin was reduced
chemically, there was a loss of inhibitory effect, suggesting the secondary structure of
trigramin was important in its binding abilities to the fibronectin receptor. It was shown
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that the trigramin had a larger effect on adhesion than the straight ORODS chain, and the
/

ORODS chain had a larger effect than that of the reduced trigramin.5

Table 1 The effect of trigramin on the adhesion of C32 melanoma cells to fibronectin a

Treatment

Concentration

Adherent cells

Percentage
Inhibition

1. No peptide

386 +/- 60

2. Trigramin

0.11 J..LM

55 +/- 26

86

3. Reduced trigramin

0.55 J..LM

299 +/- 60

23

50 J..LM

148 +/- 37

62

4. ORODS

aThe method of adhesion assay and value determinations are referenced in Knudsen, et.al.5

Predictions of the location of the RODS adhesion site gives insight into the possible
secondary structure of the attachment donlain. Located in a hydrophilic portion of the
attachment domain, the RGDS sequence may form a B- tum at a hydrophilic loop at the
surface of the molecule. At this external position, the RODS structure is available to
interact with cell surfaces. 6 The integrity of the RODS sequence has to be maintained to
insure activity of the peptide. If the arginine or the aspartic acids are deleted from the
sequence, the activity is lost. The activity is also lost if the peptide is cleaved at the
arginine, or if the glycine is substituted by a bulky valine residue. Deletions or cleavages
cause a shift on the hydrophilic loop and other changes of secondary structure are expected
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from the shift. 7 It is noted that a glycine substitution causes a loss of activity without
,/

shifting the sequence.

Figure 2 Prediction of secondary structure of 11.5 kD cell attachment domain of
fibronectin with attachment signal in a.B turn hydrophilic loop (boxed region).?

1 '
.......

. Several synthetic peptides attached to protein coated plastic beads were tested for
their adhesion inhibiting effect. All molecules that inhibited attachment had the RGDS
segment, and larger molecules generally had greater inhibitory ability. The decreased
activity with decreased size may be due to decreased stability of the smaller molecule or to
the small molecule's inability to access the substrate. The RGDS straight chain tetrapeptide
was attached to Sepharose beads at the end of a C6 spacer arm; however, there was no
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inhibitory activity displayed. Again, the small size may have limited accessibility, but also
/' the coupling method may not be efficient.?

In other experiments, inhibition of cell attachment did not occur with soluble
fibronectin or with attainable concentrations with a 30 amino acid sequence. It is
presumed to be the low affinity of a single fibronectin molecules to cell surfaces. Large
concentrations of the soluble fibronectin fragments are needed to overcome the interactions
of extra cellular matrix fibronectins. Smaller more highly soluble peptides are more likely
to have activity at lower concentrations because less interaction takes place between the
fibronectin fragments and the extra cellular matrix fibronectin. 7 However, testing many
different sequences and cOlnbinations of sequences show that poly (RGD) molecules have
the higher activity on weight basis in the inhibition of adhesions than the oligo peptide or
the monomer.8 CD spectra analysis determined the poly(RGD) sequence is a more
ordered sequence than oligo(RGD) or poly(R,G,D), with the sequence of R,G,D being
repeatedly rearranged. The CD spectra analysis using a computer program of Chang et.al.
determined the sequence structure using an average helical segment of 11 residues. The
poly(RGD) molecule has the most B-tums, with B-tums being predicted in all poly(RGD)
regions; thus giving the poly(RGD) sequence the secondary structure most favored by the
fibronectin receptor. 6
A crystal structure has been determined of an OPG2 Fab molecule with a RYD
adhesion site that ~mics the RGD adhesion site. The entire molecule consists of two
protein strands with 214 and 227 amino acids, respectively.9 From this structure, further
study of the binding site and future inhibitor development may follow. The OPG2 Fab
molecule is not fibronectin, rather it is a mouse immunoglobulin that shares a similar
binding site with fibronectin and other adhesion molecules. The adhesion site in the Fab
molecule is an arginine-tyrosine-aspartic acid (RYD) sequence, yet it mimics the RGD
sequence found in adhesion molecules. From previous experiments, the structure of the
sequence has proven to be extremely important in the activity of the molecule. The OPG2
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Fab molecule presents a clear crystalline structure of the binding site, conformation, and
secondary structure. to The resolution of the Fab molecule is 2 A considered to be
impressive for a molecule of this size. The structure of the OPG2 Fab molecule (Figure 3
and Figure 4) was acquired from the Protein Data Bank at the Brookhaven National
Laboratory, Upton, New York. 9 The structure was displayed using Sybyl Molecular
Modeling Software, version 6.2 Beta, 1995 (Tripos Associates, Inc., St. Louis, Missouri
63144) on a EVS workstation (Evans and Suthreland, Salt Lake City, Utah).
The following is a detailed view of the specific RYD binding site. The binding site
has a tyrosine that replaces the glycine of the RGD sequence; however, the backbone
stereochemistry of the site is much more important than the effects of the replacement. As
can be noted from Figure 3 the RYD binding site is on the external surface of the molecule
with little other steric hindrances in close proximity to the site. Figure 4 closely
demonstrates the openness of the binding site, as well as the extreme stereoselectivity of the
binding site. It can also be noted the pocket behind the RYD sequence open for binding.
From this OPG2 Fab crystalline structure, a more directed development of adherence
inhibitors may be synthesized in conjunction with other experimental data and molecular
modeling.

Figure 3

OPG2 Fab Mouse Immunogloblin with RYD sit~Lhat mlmlCS
RGD site 0f adhesion molecules

a

attained fran Protein Data Bank;! Brookhaven National
Laboratory, Upton, New York.

Figure 4

a

RYD binding site of OPG2 Fab Mouse Immunogloblin

a a
attained from Protein Data Bank,

Laboratory, Upton, New York.

Brookhaven National
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Specific Stereoselective Synthesis
From previous data and knowledge, specific synthetic peptide have been proposed for
development. To test the stereochemistry of the binding site, a ROD peptide was
synthesized with the residues following the aspartic acid (D) being varied to detect the
contribution of each. In the primary ROD sequence the L forms of each amino acid were
substituted with their D forms to test the structure stereoselectivity at the binding site.
Finally a peptide sequence underwent cyclicazation to prevent flexibility hoping that the
affinity of the entire molecule might be increased by a strict conformation. Various
residues following the main binding domain in the cyclic ROD were tested, and different
activities were noted from each; thus leading to the conclusion that residues following the
RGD sequence influence the stereochemistry of the RGD backbone segment itself. From
the cyclic molecule, the greatest specificity and adhesive ability was noted. The greater
activity was noted from the less flexible conformation, the more stable and specific RGD
sequence. I I
Through specific synthesis for a cyclic pentapeptide, a B- turn was by changing one
of the amino acid residues from a L conformation to that of a D conformation with internal
stabilization coming from hydrogen bonding within the peptide backbone. 12 As shown by
contrasting Figure 5 and Figure 6, the importance of an amino acid exchanging the L
conformation for the D conformation is shown. In Figure 6 there are not the double
hydrogen bonding and no B-turn as demonstrated in Figure 5.

F~gure

5

RGDFV cyclic amino acid with all residues in L
conformation except the Phe (F) groupn

11

12

Figure 6

view 1

RGDFV cyclic amino acid wi th all residues in L
conformations

view 2

;'O::J

Using molecular dynamic simulations, Gurrath et al.(13) refined the pentapeptide
/' synthesis to also include hexapeptide analogues to describe more comprehensively the
structure/activity relationship. Cyclic molecules are used to introduce conformational
constraints required of receptor binding and activity; six membered rings are synthesized to
test their inhibitory activity versus those of the tested five member cyclic rings. It was
found that the six membered rings were less active and less selective than the five member
cyclicpeptide. The correlation between structure and activity indicate that it was ring
contraction, not the position of the RGD section in a hydrophilic loop, that increased the
affinity for adhesion. 13 RGD positioning within the fibronectin's B-tum no longer
explained the importance of the cyclic compound, rather ring contraction appears to be
important. Again both conclusions validate one another to a degree; however, the work of
Gurrath showed that simply a tum was not the only requirement needed to synthesize an
effective inhibitor.
Through experimentation and various substitution, the positive and negative side
chains of the arginine and aspartic acid are found to be necessary functionalities for
binding. Equally important is the unmodified glycine spacer amino acid. 13 Shown in
Figure 7, positive and negative charges are needed for strong affinity to the receptor site.
Glycine is important to the binding capability of the RGD sequence, since a large side chain
from the glycine position may cause receptor repulsion in a streically demanding binding
pocket. A narrow- binding cleft is postulated and any large substituents would not allow
tight binding, if binding occurs at all. All steric modifications of the arginine or aspartic
acid lead to reduced binding efficiencies. Some studies have shown the ability to bind such
molecules, yet this binding is probably due to a compensation of the torsional freedom in
the amino acid side chains themselves.

Figure i

Electrical and steric requirements for binding
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-' Synthesis of cyclic RGDnFV pentapeptide
The synthesis was carried out on a Sasrin® resin solid phase using 4-methoxy2,3,6-trimethylbenzenesulfonyl (Mtr) as the arginine guanidino function protecting group,
and t-butyl ester as the aspartic acid.tfte side chain protector. No other protectors are
needed for the remaining side chains.
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In the synthesis the washings are important to insure that the peptide is made up of
only added material not of any waste material from previous steps. The fIrst step of the
synthesis is two washings for three minutes with HCONMe2, (N,N-dimethylformamide).
The second step is prewashing in 20% piperidine in HCONMe2 for three minutes also. A
deprotection of the amino acid derivative is carried out in 20% piperidine in HCONMe2
once allowing the reaction to proceed for fifteen minutes, followed by ten, three minute
washings in HCONMe2.
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The coupling of the amino acid is four moles ofFmoc (9-fluorenylmethoxycarbonyl)
/' protected amino acid derivative, and one mole of the coupling reagent of 1,3dicyclohexy1carbodiimide I-hydroxybenzotriazole, with C4H60NMe (1-methyl-2pyrrolidinone) as the basic component in EtN(iPr)2 (N,N-diisopropylethylamine). It is
~

allowed to react for apRroximately forty minutes.
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This is followed by ten, three minute washings in HCONMe2 followed by two, three
minute washings in dichloromethane. The entire procedure is repeated until the length of
the chain is produced. The chain is cleaved from the resin using 1% trifluoroacetic acid in
dichloromethane (1: 1:3). Under these conditions the side chain protecting groups are
stable.
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The cyclicazation was performed in N,N-dimethylformamide with 1.5 moles of amino acid
chain in one mole diphenlyphosphory Iazide at high dilution for four days.
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/' The pH was maintained at 8.5- 9.0 by additions of triethylamine. The side chain protecting
groups were removed with trifluoroacetic acid and a scavenger of 5% p-thiocresol.
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The peptide was purified in high performance liquid chromatography with a reverse phase
C18 3-Jlm material using a gradient ofwater/CH3CN/trifluoroacetic acid (95 : 5 : 0.2 to
20 : 80 : 1.0) over a fifteen minute period. The peptides were characterized by fast atom
bombardment mass spectroscopy, amino acid analysis and various NMR techniques. 13

Future Developments

With continued work and development, cyclic pentapeptides may have a place in
cancer treatment one day. Further refmement of the binding site stereochemistry is
important, as well as, the fragments' affinity to the fibronectin receptors of the cancer cells.
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